Song, I-H <br/><br/>
Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.  [electronic resource] 

 -  Arthritis and rheumatism  May 2010 
 - 1290-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1529-0131 
<br/><br/><label>Standard No.: </label>10.1002/art.27383  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antigens, CD20--metabolism<br/>Antirheumatic Agents--administration & dosage<br/>B-Lymphocytes--cytology<br/>Drug Resistance<br/>Female<br/>Humans<br/>Injections, Intravenous<br/>Male<br/>Middle Aged<br/>Rituximab<br/>Spondylitis, Ankylosing--drug therapy<br/>Treatment Outcome<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors